Quest Diagnostics will soon begin offering a new blood-based in-vitro diagnostic test for Alzheimer’s. The disease affects nearly 7 million Americans. The Lumipulse G pTau 217/β-Amyloid 1-42 Plasma ...
Quest Diagnostics unveiled a first-to-market blood test available for consumer purchase that helps assess the potential risk of developing Alzheimer’s disease. In adding AD-Detect, a single-blood-draw ...
The Quest AD-Detect® blood-based test panels deliver confirmatory accuracy, potentially supporting reduced reliance on ...
Quest’s two AD-Detect blood-based tests, each involving multiple biomarkers, are highly accurate at identifying Alzheimer’s disease pathology in ...
Quest Diagnostics launches first at-home blood test to assess risk of developing Alzheimer’s disease
Quest Diagnostics Inc. said Monday the first blood-based biomarker test to assess the risk of developing Alzheimer’s disease is now available for consumer purchase. The test helps assess the risk of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback